The purpose of the study is to show that the FlexAbility™ SE Ablation Catheter is safe and effective in reducing the number of Ventricular Tachycardia (VT) episodes in patients who continue to experience VT despite taking antiarrhythmic medications (medicines to prevent abnormal heart rhythms), or who are unable to take antiarrhythmic medications. Subject should be at least 18 years old. The entire duration of the study will be one year from the ablation procedure and consists of four follow up visits after the ablation procedure.